Claritev (CTEV) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
20 Mar, 2026Executive summary
Annual Meeting scheduled for April 29, 2026, to be held virtually, with record date March 6, 2026.
2025 marked a return to positive revenue growth, improved Adjusted EBITDA, and strong free cash flow.
Strategic focus on Vision 2030, digital transformation, and disciplined growth through technology and AI.
Expanded into new vertical markets and secured over $67 million in new Annual Contract Value.
Voting matters and shareholder proposals
Four proposals: (1) Election of four Class III directors, (2) Ratification of PwC as auditor, (3) Advisory say-on-pay vote, (4) Approval of amendment to 2020 Omnibus Incentive Plan.
Board recommends voting FOR all proposals.
Shareholders can vote by internet, phone, or mail; virtual attendance allows for proxy revocation and live voting.
Board of directors and corporate governance
Board consists of ten members with one vacancy; 80% are independent.
Board divided into three staggered classes; Lead Independent Director role in place.
Committees: Audit, Compensation, Nominating & Corporate Governance, and Risk—all fully independent.
Board diversity in experience, background, gender, age, and race.
Annual board and committee self-evaluations and director education programs.
Latest events from Claritev
- 2024 net loss surged on a $1.49B impairment as transformation and rebranding drive long-term optimism.CTEV
Q4 20249 Jul 2026 - Q1 2025 revenue was $231.3M, net loss narrowed, and transformation advanced.CTEV
Q1 20259 Jul 2026 - Six new market segments, tech innovation, and a $200M pipeline drive growth into 2026.CTEV
BofA Securities Leveraged Finance Conference 20258 Jul 2026 - Transformation and innovation drive growth, profitability, and expanded market reach.CTEV
44th Annual J.P. Morgan Healthcare Conference8 Jul 2026 - Record bookings, tech investment, and strong client ties drive ambitious 2030 growth targets.CTEV
Bank of America Global Healthcare Conference 202614 May 2026 - Q1 2026 revenue grew 5.8% to $244.7M, with margin gains but continued net losses.CTEV
Q1 20267 May 2026 - All proposals, including director elections and plan amendments, were approved without contest.CTEV
AGM 202629 Apr 2026 - 2026 guidance targets $980M–$1B revenue, 61–62% EBITDA margin, and AI-driven growth.CTEV
Investor Day 202629 Apr 2026 - Definitive additional proxy materials outline voting procedures for the upcoming meeting.CTEV
Proxy filing20 Mar 2026